12:00 AM
 | 
Apr 06, 2009
 |  BC Week In Review  |  Company News  |  Deals

Altea, Amylin, Eli Lilly deal

Altea granted Lilly and Amylin exclusive, worldwide rights to develop and commercialize transdermal exenatide using Altea's PassPort Transdermal Delivery System. The once daily transdermal exenatide patch is in Phase I testing for...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >